Baricitinib
Composition: Each film coated
tablet contains Baricitinib INN 2.00 mg.
Indication: Baricitinib is a
Janus kinase (JAK) inhibitor indicated for the treatment of adult patients with
moderately to severely active rheumatoid arthritis who have had an inadequate response
to one or more TNF blockers. Limitation of Use: • Not recommended for use in combination
with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressant’s such
as azathioprine and cyclosporine. • For the treatment of COVID-19 in
hospitalized adults requiring supplemental oxygen, non-invasive or invasive
mechanical ventilation, or ECMO. • It is indicated for the treatment of adult
patients with severe alopecia areata.
Dosage and administration: The recommended
dose of Barictinib is 2 mg once daily. It may be used as monotherapy or in
combination with methotrexate or other DMARDs. It is given orally with or
without food. Lymphopenia: It should be avoided the initiation or interrupt in
patients with an Absolute Lymphocyte Count less than 500 cells/mm3. Alopecia
Areata: 2mg once daily. Increase to 4mg once daily, if the response to
treatment is not adequate. Or, as directed by the registered physician.
Administration instruction: • Rheumatoid
Arthritis and Alopecia Areata: Avoid initiation or interrupt Barinib in
patients with anemia (hemoglobin<8 g/dL) or neutropenia (ANC <1000 cells/mm3).
•
COVID-19: Avoid initiation or interrupt Barinib in patients with lymphopenia
(ALC <200 cells/mm3) or neutropenia (ANC <500 cells/mm3).
Use in Pregnancy and lactation: Pregnancy: This
medicine may cause fetal harm. Lactation: Advise not to breastfeed.
Packing: Each box
contains 60's tablets in a blister pack.
